SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

Shuqui Qin; Jin Li; Aiping Zhou; Yanqiao Zhang; Xianglin Yuan; Liangjun Zhu; Baoli Qin; Shan Zeng; Lin Shen; Ying Yuan; Weibo Wang; Jun Liang; Xianwen Zhang; Feng Ye; Ping Chen; Huaizhang Wang; Zhenyan Yu; Lu Yue; Yong Fang; Jianping Xiong; Jianwei Yang; Yiye Wan; Xianli Yin; Wenling Wang; Nong Xu; Xiaohong Wang; Zemin Xiao; Huafang Su; Ying Wang; Kangsheng Gu; Shuiping Tu; Zishu Wang; Bo Liu; Xiaohua Hu; Weixian Liu; Xiaofeng Li

doi:10.1002/cac2.12586

Cancer Communications ›› 2024, Vol. 44 ›› Issue (08) : 910-914. DOI: 10.1002/cac2.12586

LETTER TO THE JOURNAL

SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study

Shuqui Qin¹ ,
Jin Li² ,
Aiping Zhou³ ,
Yanqiao Zhang⁴ ,
Xianglin Yuan⁵ ,
Liangjun Zhu⁶ ,
Baoli Qin⁷ ,
Shan Zeng⁸ ,
Lin Shen⁹ ,
Ying Yuan¹⁰ ,
Weibo Wang¹¹ ,
Jun Liang¹² ,
Xianwen Zhang¹³ ,
Feng Ye¹⁴ ,
Ping Chen¹⁵ ,
Huaizhang Wang¹⁶ ,
Zhenyan Yu¹⁷ ,
Lu Yue¹⁸ ,
Yong Fang¹⁹ ,
Jianping Xiong²⁰ ,
Jianwei Yang²¹ ,
Yiye Wan²² ,
Xianli Yin²³ ,
Wenling Wang²⁴ ,
Nong Xu²⁵ ,
Xiaohong Wang²⁶ ,
Zemin Xiao²⁷ ,
Huafang Su²⁸ ,
Ying Wang²⁹ ,
Kangsheng Gu³⁰ ,
Shuiping Tu³¹ ,
Zishu Wang³² ,
Bo Liu³³ ,
Xiaohua Hu³⁴ ,
Weixian Liu³⁵ ,
Xiaofeng Li³⁶

Author information +

¹. Department of Oncology, Nanjing Tianyinshan Hospital, Nanjing, Jiangsu, P. R. China

². Department of Medical Oncology, Shanghai East Hospital, Shanghai, P. R. China

³. Department of Medical Oncology, Cancer Hospital Chinese Academy of Medical Sciences, Beijing, P. R. China

⁴. Department of Gastroenterology, Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, P. R. China

⁵. Department of Medical Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology,Wuhan, Hubei, P. R. China

⁶. Department of Medical Oncology, Jiangsu Cancer Hospital, Nanjing, Jiangsu, P. R. China

⁷. Department of Gastroenterology, Liaoning Cancer Hospital & Institute, Shenyang, Liaoning, P. R. China

⁸. Department of Oncology, Xiangya Hospital, Central South University, Changsha, Hunan, P. R. China

⁹. Department of Medical Oncology, Beijing Cancer Hospital, Beijing, P. R. China

¹⁰. Department of Medical Oncology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

¹¹. Department of Chemotherapy, Shandong Provincial Hospital, Jinan, Shandong, P. R. China

¹². Department of Medical Oncology, Peking University International Hospital, Beijing, P. R. China

¹³. Department of Medical Oncology, Northern Jiangsu People’s Hospital, Yangzhou, Jiangsu, P. R. China

¹⁴. Department of Medical Oncology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, P. R. China

¹⁵. Department of Medical Oncology, General Hospital of Ningxia Medical University, Yinchuan, Ningxia, P. R. China

¹⁶. Department of Integrated Chinese and Western Medicine, Henan Cancer Hospital, Zhengzhou, Henan, P. R. China

¹⁷. Department of Medical Oncology, Mudanjiang Tumor Hospital, Mudanjiang, Heilongjiang, P. R. China

¹⁸. Department of Oncology, Qingdao Municipal Hospital (Group), Qingdao, Shandong, P. R. China

¹⁹. Department of Medical Oncology, Sir Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

²⁰. Department of Medical Oncology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P. R. China

²¹. Department of Abdominal Oncology, Fujian Cancer Hospital, Fuzhou, Fujian, P. R. China

²². Department of Gastroenterology, Jiangxi Cancer Hospital, Nanchang, Jiangxi, P. R. China

²³. Department of Gastroenterology and Urology, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, Hunan, P. R. China

²⁴. Department of Abdominal Oncology, The Affiliated Hospital of Guizhou Medical University, Guizhou, Guizhou, P. R. China

²⁵. Department of Medical Oncology, The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, Zhejiang, P. R. China

²⁶. Department of Abdominal Oncology, Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China

²⁷. Department of Oncology, The First People’s Hospital of Changde City, Changde, Hunan, P. R. China

²⁸. Department of Radiotherapy, The First Affiliated Hospital of Wenzhou Medical University,Wenzhou, Zhejiang, P. R. China

²⁹. Department of Medical Oncology, Shengjing Hospital of China Medical University, Shenyang, Liaoning, P. R. China

³⁰. Department of Medical Oncology, The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, P. R. China

³¹. Department of Medical Oncology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, P. R. China

³². Department of Medical Oncology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, P. R. China

³³. Department of Gastroenterology, Shandong Cancer Hospital & Institute, Jinan, Shandong, P. R. China

³⁴. Department of Medical Oncology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, P. R. China

³⁵. Department of Medical Oncology, Binzhou People’s Hospital, Binzhou, Shandong, P. R. China

³⁶. Department of Medical Oncology, Quanzhou First Hospital, Quanzhou, Fujian, P. R. China

lijin@csco.org.cn

Show less

History +

Cite this article

EndNote

Ris (Procite)

Bibtex

Download citation ▾

Shuqui Qin, Jin Li, Aiping Zhou, Yanqiao Zhang, Xianglin Yuan, Liangjun Zhu, Baoli Qin, Shan Zeng, Lin Shen, Ying Yuan, Weibo Wang, Jun Liang, Xianwen Zhang, Feng Ye, Ping Chen, Huaizhang Wang, Zhenyan Yu, Lu Yue, Yong Fang, Jianping Xiong, Jianwei Yang, Yiye Wan, Xianli Yin, Wenling Wang, Nong Xu, Xiaohong Wang, Zemin Xiao, Huafang Su, Ying Wang, Kangsheng Gu, Shuiping Tu, Zishu Wang, Bo Liu, Xiaohua Hu, Weixian Liu, Xiaofeng Li. SALIRI-based (raltitrexed plus irinotecan) therapy as a second-line treatment for patients with metastatic colorectal cancer (SALLY): A prospective, multicenter, non-interventional, registry study. Cancer Communications, 2024, 44(08): 910‒914 https://doi.org/10.1002/cac2.12586

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Xu R, Wang W, Zhu B, Lin X, Ma D, Zhu L, et al. Disease characteristics and treatment patterns of Chinese patients with metastatic colorectal cancer: a retrospective study using medical records from China. BMC Cancer. 2020; 20(1): 131. CrossRef Google scholar

[2]	Francipane MG, Bulanin D, Lagasse E. Establishment and characterization of 5-fluorouracil-resistant human colorectal cancer stem-like cells: tumor dynamics under selection pressure. Int J Mol Sci. 2019; 20(8): 1817. CrossRef Google scholar

[3]	Yang W, Zheng H, Lv W, Zhu Y. Current status and prospect of immunotherapy for colorectal cancer. Int J Colorectal Dis. 2023; 38(1): 266. CrossRef Google scholar

[4]

Zhang X, Duan R, Wang Y, Liu X, Zhang W, Zhu X, et al. FOLFIRI (folinic acid, fluorouracil, and irinotecan) increases not efficacy but toxicity compared with single-agent irinotecan as a second-line treatment in metastatic colorectal cancer patients: a randomized clinical trial. Ther Adv Med Oncol. 2022; 14: 17588359211068737.

CrossRef Google scholar

[5]	Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol. 2004; 22(2): 229-237. CrossRef Google scholar

[6]

Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausová J, Macarulla T, et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol. 2012; 30(28): 3499-3506.

CrossRef Google scholar

[7]	Cui C, Shu C, Yang Y, Liu J, Shi S, Shao Z, et al. XELIRI compared with FOLFIRI as a second-line treatment in patients with metastatic colorectal cancer. Oncol Lett. 2014; 8(4): 1864-1872. CrossRef Google scholar

[8]

Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, et al. Efficacy and safety of bevacizumab in combination with fluoropyrimidine-based chemotherapy for the treatment of advanced metastatic colorectal cancer: a prospective, non-intervention an. post-marketing multicenter clinical study (REACT). Chinese Clinical Oncology. 2016; 21(10): 865-873.

[9]	Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, et al. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phas. IV trial. Chin J Cancer Res. 2021; 33(4): 490-499.

[10]	Zhu JL, Li S, Zhu C. Efficacy and safety of the combination of bevacizumab with raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): An interim analysis of a multicenter phase II trial. Ann Oncol. 2019; 30: ix39. CrossRef Google scholar